Table 3 Functional and inflammatory characteristics according to the inflammatory phenotype
| Â | Paucigranulocytic phenotype | Eosinophilic phenotype | Neutrophilic phenotype | Mixed granulocytic phenotype |
|---|---|---|---|---|
IgE, kU/l | 84 (1–7338) | 211 (3–17183)*** | 107 (2–7338) | 346 (1–2063) |
Blood eosinophils,/mm3 | 160 (0–1220) | 360 (0–3220)*** | 170 (20–1020) | 420 (190–3040)*** |
Blood eosinophils,% | 2 (0–13) | 4.5 (0–26)*** | 1.9 (0.2-15) | 5 (1.3-30)*** |
Blood neutrophils,/mm3 | 4030 (76–11080) | 4220 (1820–15410) | 5000 (2070–10440) | 4245 (3520–6170) |
Blood neutrophils,% | 59 (27–82) | 55 (32–91)* | 62 (42–80) | 59 (43–68) |
FEV1,% predicted | 90 ± 17 | 80 ± 20*** | 79 ± 20*** | 72 ± 14*** |
FEV1/FVC,% | 77 ± 9 | 71 ± 10*** | 72 ± 11*** | 69 ± 9*** |
TLC,% predicted | 99 ± 16 | 102 ± 18 | 102 ± 18 | 101 ± 14 |
FRC,% predicted | 103 ± 27 | 104 ± 19 | 119 ± 32 | 111 ± 22 |
KCO,% predicted | 90 ± 19 | 92 ± 21 | 91 ± 19 | 100 ± 10 |
PC20, mg/ml | 4.42 (0.13-16) | 2.02 (0.025-16)** | 3.22 (0.05-16) | 1.08 (0.53-2.2)** |
Reversibility,% | 8 ± 9 | 15 ± 17** | 8 ± 10 | 12 ± 10 |
Sputum eosinophils,% | 0.4 (0–2.9) | 18 (3–94) | 0.2 (0–2.8) | 4.3 (3–8) |
Sputum neutrophils,% | 41 (0–76) | 33 (0–76) | 87 (77 – 100) | 82 (76–92) |
Fibrinogen, g/l | 3.1 (2–6.3) | 3.1 (2–7.2) | 3.3 (1.9-10) | 4.1 (2.7-6.3)* |
CRP, mg/l | 1.6 (0.2-14) | 1.8 (0.2-14) | 2.3 (0.2-10) | 1.9 (1.1-6) |
FENO, ppb | 16 (1–128) | 53 (2–247)*** | 22 (0–192) | 41 (12–161)* |
ACQ | 1.82 ± 1.15 | 2.16 ± 1.36* | 2.09 ± 1.88 | 2.09 ± 1.16 |
Global AQLQ | 4.6 ± 1.3 | 4.58 ± 1.34 | 4.76 ± 1.46 | 4.45 ± 1.74 |
-Emotion | 4.92 ± 1.35 | 4.57 ± 1.63 | 4.9 ± 1.76 | 4.64 ± 1.83 |
-Symptoms | 4.46 ± 1.46 | 4.42 ± 1.43 | 4.65 ± 1.54 | 4.39 ± 1.5 |
-Activity | 4.71 ± 1.36 | 4.79 ± 1.44 | 4.84 ± 1.49 | 4.55 ± 1.80 |
-Environnement | 4.48 ± 1.50 | 4.55 ± 1.55 | 4.81 ± 1.67 | 4.70 ± 2.15 |